BR112016030018A8 - sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal - Google Patents

sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal

Info

Publication number
BR112016030018A8
BR112016030018A8 BR112016030018A BR112016030018A BR112016030018A8 BR 112016030018 A8 BR112016030018 A8 BR 112016030018A8 BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A8 BR112016030018 A8 BR 112016030018A8
Authority
BR
Brazil
Prior art keywords
salt
lpa receptor
pharmaceutical composition
receptor antagonist
substituted heterocyclic
Prior art date
Application number
BR112016030018A
Other languages
English (en)
Other versions
BR112016030018A2 (pt
BR112016030018B1 (pt
Inventor
Iwase Noriaki
Nishida Hiroshi
Okudo Makoto
Ito Masaaki
Kono Shigeyuki
Matoyama Masaaki
Ushiyama Shigeru
Okanari Eiji
Matsunaga Hirofumi
Nishikawa Kenji
Kimura Tomio
Original Assignee
Ube Industries
Ube Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries, Ube Corp filed Critical Ube Industries
Publication of BR112016030018A2 publication Critical patent/BR112016030018A2/pt
Publication of BR112016030018A8 publication Critical patent/BR112016030018A8/pt
Publication of BR112016030018B1 publication Critical patent/BR112016030018B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SAL COMPOSTO DE HETEROCÍCLICO SUBSTITUÍDO COM HALOGÊNIO. É fornecido um novo sal composto de tiofeno substituído com a-halogênio que tem uma potente ação antagonista do receptor de LPA e é útil como um produto farmacêutico. Um sal representado pela fórmula geral (I): em que R é um átomo de hidrogênio ou um grupo metóxi; X é um átomo de halogênio; A é selecionado do grupo que consiste nos seguintes grupos: A; M é um metal alcalino ou um metal alcalinoterroso e n é 1 quando M é um metal alcalino e é 2 quando M é um metal alcalino-terroso].
BR112016030018-1A 2014-06-27 2015-06-26 Sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal BR112016030018B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014132413 2014-06-27
JP2014-132413 2014-06-27
PCT/JP2015/068575 WO2015199234A1 (ja) 2014-06-27 2015-06-26 ハロゲン置換へテロ環化合物の塩

Publications (3)

Publication Number Publication Date
BR112016030018A2 BR112016030018A2 (pt) 2017-08-22
BR112016030018A8 true BR112016030018A8 (pt) 2023-05-09
BR112016030018B1 BR112016030018B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
BR112016030018A2 (pt) 2017-08-22
JP6579103B2 (ja) 2019-09-25
US20170158663A1 (en) 2017-06-08
EP3162801B1 (en) 2020-07-22
ES2824801T3 (es) 2021-05-13
KR102433588B1 (ko) 2022-08-19
JPWO2015199234A1 (ja) 2017-04-27
EP3162801A4 (en) 2018-01-24
CN106458964A (zh) 2017-02-22
MX2016017371A (es) 2017-05-01
US10023554B2 (en) 2018-07-17
RU2689315C2 (ru) 2019-05-27
KR20170016988A (ko) 2017-02-14
RU2017102513A (ru) 2018-07-27
AU2015281021B2 (en) 2019-03-14
AU2015281021B9 (en) 2019-03-28
WO2015199234A1 (ja) 2015-12-30
CA2953472A1 (en) 2015-12-30
CN106458964B (zh) 2019-11-22
MX370408B (es) 2019-12-11
AU2015281021A1 (en) 2017-01-19
EP3162801A1 (en) 2017-05-03
CA2953472C (en) 2022-08-02
RU2017102513A3 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
TN2018000262A1 (en) Substituted piperidine compound and use there of.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2016000581A1 (es) Pesticidas de azol bicíclicos sustituidos por heterociclo.
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
TN2018000424A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
MX2016011992A (es) Derivados de piperidina-diona.
UY34833A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano RORy
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
BR112017006240A2 (pt) novos compostos
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
MX2016017371A (es) Sal de compuesto heterociclico sustituido con halogeno.
RS54730B1 (sr) Inhibitori beta sekretaze
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2017009288A (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3.
CY1125355T1 (el) Πεντακυκλικη ενωση
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina
BR112015028871A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UBE CORPORATION (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2015, OBSERVADAS AS CONDICOES LEGAIS